Pneumonia Therapeutics Market Size Worth $22.9 Billion By 2025: Grand View Research, Inc.

Wednesday, July 19, 2017 Research News
Email Print This Page Comment bookmark
Font : A-A+

SAN FRANCISCO, July 19, 2017 /PRNewswire/ --

The global pneumonia therapeutics market is expected to reach

USD 22.9 billion by 2025, according to a new report by Grand View Research, Inc. This market is anticipated to grow at an unprecedented rate owing to the increasing prevalence of pneumococcal disease globally. The increasing
demand for pneumonia therapeutics is a result of unmet clinical needs in emerging as well as developed regions. Increasing focus of healthcare organizations on raising awareness and issuing guidelines for efficient management of pneumococcal disease is predicted to broaden the scope for growth over the coming years. For instance, Infectious Diseases Society of America/American Thoracic Society has issued guidelines on the management of community-acquired pneumonia. According to a white paper released by American Academy of Family Physicians, adherence to these guidelines has resulted in positive patient outcomes during the treatment of community-acquired bacterial pneumonia in patients.

     (Logo: )

Moreover, growing R&D activities in life sciences are anticipated to create positive impact on the market over the coming years. Consequentially, increase in number of products, currently being reviewed under clinical trials, is anticipated to fuel the overall growth. In the present scenario, there are 12 drugs under investigation in phase III trials, 4 drugs under phase II, and 3 drugs under phase I trial. The aforementioned factors exemplify the consistent efforts being made by the market players. For instance, Omadacycline, a tetracycline under phase III clinical trial, developed by Paratek Pharmaceuticals is being investigated for use in the treatment of ventilator-associated and community-acquired bacterial pneumonia.

Browse full research report with TOC on "Pneumonia Therapeutics Market Analysis By Product (Drugs, Branded, Quinolones, Aminopenicillins, Macrolides, B-lactamase Inhibitors, Cephalosporins, Tetracyclines, Glycopeptides, Generics, Vaccines, Oxygen Therapy) And Segment Forecasts, 2014 - 2025" at:

Further key findings from the report suggest: 

  • Vaccines accounted for the largest share in the product segment in 2016. This can be attributed to their high efficacy and growing inclination of patients toward preventive measures
  • They are also expected to grow at a lucrative rate owing to the recommendation by WHO for their inclusion in national immunization programs
  • Drugs are expected to witness moderate growth rate throughout the forecast period. This is believed to be a result of the infiltration of generic drugs that are more cost-efficient.
  • North America accounted fora substantial share in the market owing to increasing number of supportive government initiatives and high awareness levels amongst the end-users
  • Asia Pacific is expected to witness exponential CAGR during the forecast period owing to its high disease burden and continual infrastructural upgradation of research & manufacturing facilities in the region
  • High competition has been observed in the market, where major players adopt strategies such as new product development, collaborations, and strategic agreements to gain market share

Browse related reports by Grand View Research: 

  • Biopharmaceutical Market -
  • ePharmacies Market -
  • Non-Small Cell Lung Cancer Market -
  • Pharmaceutical Manufacturing Market -

Grand View Research has segmented the global pneumonia therapeutics market on the basis of product and region: 

  • Pneumonia Therapeutics Product Outlook (Revenue, USD Million, 2014 - 2025)
    • Drugs
      • Branded
        • Quinolones
        • Aminopenicillins
        • Macrolides
        • B-lactamase Inhibitors
        • Cephalosporins
        • Tetracyclines
        • Glycopeptide Antibiotics
        • Carbapenems
        • Others
      • Generics
        • Quinolones
        • Macrolides
        • Others
    • Vaccines
    • Oxygen Therapy
  • Pneumonia Therapeutics Regional Outlook (Revenue, USD Million, 2014 - 2025)
    • North America
      • U.S.
      • Canada
    • Europe
      • Germany
      • UK
    • Asia Pacific
      • Japan
      • China
      • India
    • Latin America
      • Brazil
      • Mexico
    • Middle East & Africa
      • South Africa

Read Our Blog:

About Grand View Research 

Grand View Research, Inc. is a U.S. based market research and consulting company, registered in the State of California and headquartered in San Francisco. The company provides syndicated research reports, customized research reports, and consulting services. To help clients make informed business decisions, we offer market intelligence studies ensuring relevant and fact-based research across a range of industries, from technology to chemicals, materials and healthcare.

Contact: Sherry James Corporate Sales Specialist, USA Grand View Research, Inc Phone: +1-415-349-0058 Toll Free: +1-888-202-9519 Email:


SOURCE Grand View Research, Inc.

Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions

News A - Z


News Search

Medindia Newsletters

Subscribe to our Free Newsletters!

Terms & Conditions and Privacy Policy.

Find a Doctor

Press Release Category

Press Release Archive

Stay Connected

  • Available on the Android Market
  • Available on the App Store